A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C

Brief description of study

This study is designed for patients with acute myeloid leukemia.

The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 and the WEE1 inhibitor ZN-c3 in subjects with acute myeloid leukemia (ZN-d50004C).

Clinical Study Identifier: s22-01161

Principal Investigator: Mohammad Maher Abdul Hay.

Other Investigators: Shella Saint Fleur-Lominy, Kenny Tai, Jun Han Choi.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies